An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Study Identifier:
ACH443-904
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Human Immunodeficiency Virus
Study Drug
- Drug: Elvucitabine
Date
May 2008 - Mar 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years
Requirements Information
Sex
Female & Male
Age
18 - 65 Years
Study Details
Medical Condition
- Human Immunodeficiency Virus
Study Drug
- Drug: Elvucitabine
Date
May 2008 - Mar 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years years
Requirements Information
Protocol Summary
Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
Trial Locations
Location
Status
Location
Clinical Trial Site
Orlando, Florida, United States, 32803
Status
N/A
Location
Clinical Trial Site
Pensacola, Florida, United States, 32504
Status
N/A
Location
Clinical Trial Site
Newark, New Jersey, United States, 07102
Status
N/A
Location
Clinical Trial Site
Austin, Texas, United States, 78705
Status
N/A
Location
Clinical Trial Site
Dallas, Texas, United States, 75204
Status
N/A